United States Pet Veterinary Diet Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

The United States Pet Veterinary Diet Market was valued at USD 1.8 Billion in 2025 and is projected to reach USD 3.2 Billion by 2035, expanding at a CAGR of 7.5%. Veterinary diets - therapeutic pet foods formulated to manage specific medical conditions under veterinary supervision - represent the premium tier of the USD 60+ billion US pet food market. Conditions addressed include chronic kidney disease, diabetes mellitus, digestive sensitivity disorders, urinary tract disease, obesity, and hepatic disease. The US pet humanisation trend - manifested through record pet ownership levels (approximately 70% of US households owning pets), elevated pet healthcare spending, and the growing willingness of pet owners to invest in clinical nutrition as a disease management tool - is the primary structural growth driver. The American Veterinary Medical Association's clinical nutrition guidelines increasingly recognise therapeutic diets as first-line management tools for chronic conditions in dogs and cats, supporting veterinarian prescription behaviour that drives sales through clinical channels.

Key Market Trends & Insights

• Pet Humanisation and Healthcare Premiumisation: US pet owners are allocating an increasing share of household spending to pet health management - including therapeutic diets - treating companion animals with the same level of clinical care investment historically reserved for human family members.
• Chronic Disease Prevalence in Companion Animals: Canine and feline chronic kidney disease, diabetes, and obesity prevalence are increasing as the US pet population ages, directly expanding the clinical nutrition addressable market for condition-specific therapeutic diets.
• Veterinary E-Commerce Channel Growth: Online veterinary diet dispensing - through platforms including VetSource, Chewy's Autoship, and veterinary practice online pharmacies - is expanding therapeutic diet accessibility beyond clinic visits, driving reorder rates and increasing household penetration.

Market Size & Forecast Highlights

• Market Value 2025: USD 1.8 Billion, projected to reach USD 3.2 Billion by 2035 at 7.5% CAGR.
• Renal and digestive sensitivity diets represent the two largest sub-product segments at approximately 40% and 25% of market value respectively.
• Dogs account for approximately 65% of market value; cats represent approximately 32%.
• Veterinary clinics remain the primary distribution channel at approximately 50%; online channels growing fastest at approximately 20% CAGR.

Key Takeaways

• US pet food market exceeds USD 60 billion annually; veterinary diets represent approximately 3% by value but are the highest-margin and fastest-growing segment.
• Hill's Pet Nutrition (Colgate-Palmolive) and Royal Canin (Mars) collectively hold approximately 75-80% of US veterinary diet market value.
• AAFCO (Association of American Feed Control Officials) nutritional adequacy statements and veterinary prescription requirement create regulatory barriers sustaining premium brand dominance.

Summary Table

Market Dynamics & Key Trends

1. Aging US Pet Population and Chronic Disease Management

The US companion animal population is aging - reflecting longer pet lifespans enabled by veterinary advances - with an estimated 35% of US dogs and 40% of US cats being 7 years or older. Chronic kidney disease affects approximately 1 in 10 dogs and 1 in 3 cats over age 15; diabetes mellitus prevalence is estimated at 1 in 200-500 dogs and 1 in 100-500 cats. These age-related conditions create sustained long-term prescription diet demand from pet owners committed to managing chronic conditions through clinical nutrition rather than pharmaceutical management alone. The International Renal Interest Society (IRIS) staging system for canine and feline CKD explicitly recommends therapeutic renal diets at Stage 2 and above, creating a clinical evidence framework that supports veterinarian diet recommendation behaviour.

2. Premiumisation and Pet Humanisation

Americans spent approximately USD 147 billion on their pets in 2023 (APPA), with veterinary care and health products the fastest-growing spending categories. The COVID-19 pandemic accelerated pet adoption - adding approximately 23 million US households to pet ownership - creating a large cohort of committed new pet owners who are now encountering their first pet chronic disease diagnoses and initiating therapeutic diet regimens. The 'treat pets like family' ethos prevalent among millennial pet owners - who represent approximately 32% of US pet owners - translates directly into willingness to invest in clinical nutrition despite therapeutic diet premium pricing of USD 80-USD 200 per month versus USD 30-USD 60 for mainstream pet food.

3. Online Dispensing and Autoship Growth

VetSource, Chewy's Practice Hub, Vetsource, and direct veterinary practice e-commerce platforms are enabling seamless therapeutic diet prescription fulfilment with home delivery - removing the in-clinic purchase barrier that historically limited compliance with long-term dietary management. Chewy's Autoship subscription - with approximately 35 million active subscriptions - provides particularly strong therapeutic diet retention as subscription delivery removes the friction of repeated clinic visits for refills. Online dispensing platforms provide veterinary practices with commission revenue that sustains therapeutic diet recommendation behaviour.

4. Expanding Condition-Specific Diet Innovation

Major veterinary diet manufacturers are expanding their condition-specific portfolio beyond legacy renal and digestive offerings to cover joint health, cognitive dysfunction, anxiety management, and multi-condition combination diets addressing comorbid patients. Hill's Prescription Diet's c/d Multicare Stress line - combining urinary health and stress management - demonstrates the product innovation addressing the multi-condition senior pet population. Royal Canin Satiety Support and Diabetic formulations are supported by clinical trials published in peer-reviewed veterinary nutrition journals, creating an evidence-based prescribing rationale that differentiates premium therapeutic diets from over-the-counter 'health' pet foods.

Recent Developments

Hill's Prescription Diet Innovation (2024)

Hill's Pet Nutrition launched its Prescription Diet k/d + Mobility formulation - combining renal disease management with omega-3 and green-lipped mussel joint support - targeting the high-prevalence comorbid CKD/osteoarthritis senior dog population. The dual-condition formulation addresses pet owner demand for simplified multi-condition dietary management.

Royal Canin Veterinary Nutrition Digital Platform (2024)

Royal Canin launched an enhanced US veterinary digital platform - providing veterinary professionals with clinical nutrition decision support tools, patient diet calculators, and seamless practice management system integration for therapeutic diet prescriptions. The platform improves veterinarian therapeutic diet recommendation efficiency and enhances prescription compliance tracking.

Purina Pro Plan Veterinary Diets DM Expansion (2024)

Nestlé Purina expanded its Pro Plan Veterinary Diets Diabetes Management (DM) range with a new feline wet food variant and improved carbohydrate management formulation supported by internal clinical research. Purina's investment in feline diabetic diet innovation targets the growing US feline diabetes management market where prescription diet uptake remains below its clinical potential.

Industry Segmentation

By Sub Product

Renal diets are the largest segment at approximately 28% of market value, driven by the high prevalence of CKD in senior dogs and cats and the strong clinical evidence base supporting dietary phosphorus restriction as primary CKD management. Digestive sensitivity diets follow at approximately 22%, serving dogs and cats with inflammatory bowel disease, food sensitivities, and exocrine pancreatic insufficiency. Diabetes management diets and oral care diets serve specialised clinical populations.

Key Insight: Renal diets command the highest average monthly treatment cost per patient - USD 100-200/month - due to the need for complete dietary transition and long-term management, making them the highest lifetime value therapeutic diet segment despite not having the largest patient population.

By Pet Type

Dogs represent approximately 65% of US veterinary diet market value, reflecting the US dog population of approximately 90 million and the higher household spending on canine versus feline healthcare. Cats represent approximately 32% of market value - with feline renal and urinary diets representing particularly high-usage segments given feline CKD prevalence rates exceeding canine. Other small animals (rabbits, ferrets) represent a niche therapeutic diet segment.

Key Insight: Feline therapeutic diets are growing faster than canine - at approximately 10% versus 7% CAGR - driven by growing recognition of the exceptionally high prevalence of chronic kidney disease in senior cats and improved compliance through enhanced palatability formulations.

By Distribution Channel

Veterinary clinics remain the primary distribution channel at approximately 50% of market value, providing prescription authorisation gatekeeping and clinical recommendation authority that sustains premium brand pricing. Online channels (VetSource, Chewy Practice Hub) account for approximately 25% and growing fastest at approximately 20% CAGR. Specialty pet stores (PetSmart Veterinary section, independent specialty retailers) account for approximately 20%.

Key Insight: Online therapeutic diet dispensing is the fastest-growing channel, growing at approximately 20% CAGR, as veterinary practices establish online dispensing stores and pet owners embrace the convenience of Autoship delivery for long-term condition management.

Market Share & Competitive Landscape

The US veterinary diet market is highly concentrated with Hill's Pet Nutrition and Royal Canin collectively accounting for approximately 75-80% of market value. Purina Pro Plan Veterinary Diets holds approximately 12-15% share. Smaller specialist brands (Rayne Clinical Nutrition, Blue Buffalo Natural Veterinary Diet) compete in niche segments. Brand switching is limited by clinical inertia and patient dietary adaptation.

Competitive Profiles

Hill's Pet Nutrition (United States/Colgate-Palmolive)

Hill's Prescription Diet brand - the originator of the US therapeutic pet food category founded by Dr. Mark Morris Sr. in 1948 - maintains leadership through the broadest condition-specific diet portfolio, strong clinical evidence programmes, and deep veterinarian education relationships. Hill's Science Diet and Prescription Diet dual-brand structure serves both general wellness and clinical nutrition segments.

Royal Canin (France/Mars Petcare)

Royal Canin's Veterinary Health Nutrition range provides condition-specific diets across renal, gastrointestinal, cardiac, and weight management indications with breed-specific formulations for premium differentiation. Royal Canin's veterinary nutrition congress sponsorship and clinical research investment maintain its position as the premium veterinary nutrition brand.

Purina Pro Plan Veterinary Diets (Switzerland/Nestlé Purina)

Nestlé Purina's Pro Plan Veterinary Diets compete across digestive, renal, urinary, and obesity management therapeutic diet categories, supported by Purina's research facilities at the Purina Pet Care Center. Purina's integration with its mainstream Pro Plan brand provides strong brand equity transfer and consumer trust that supports therapeutic diet adoption.

Rayne Clinical Nutrition (Canada)

Rayne Clinical Nutrition competes in the premium prescription veterinary diet segment with novel protein and hydrolysed protein diets targeting food allergy and inflammatory bowel disease patients. Rayne's veterinary practice direct distribution model and nutritionist support services target specialist veterinary practices.

Others: Blue Buffalo Natural Veterinary Diet (General Mills), Iams Veterinary Formula (Mars), and Farmina Vet Life serve distinct US veterinary diet market niches.

Key Highlights

• US Pet Veterinary Diet Market valued at USD 1.8B in 2025, forecast to reach USD 3.2B by 2035 at 7.5% CAGR.
• Hill's Prescription Diet and Royal Canin collectively hold approximately 75-80% of US market value.
• Renal diets largest sub-product at approximately 28%; feline therapeutic diets growing fastest at approximately 10% CAGR.
• Online dispensing (Chewy Practice Hub, VetSource) growing at approximately 20% CAGR - fastest distribution channel.
• US pet spending exceeded USD 147B in 2023; therapeutic diets are highest-margin segment despite representing ~3% of total.
• Aging US pet population (35% of dogs, 40% of cats aged 7+) structurally expanding chronic disease therapeutic diet demand.